

## **Supplementary Information**

**Table S1.** Number of eyes (and individuals) with 0, 1 or 2 risk alleles at each of the 7 risk variants in analyses of progression to advanced AMD (GA or CNV), progression to GA only and progression to CNV only.


		Advanced AMD (GA or CNV)				GA				CNV			
		Risk alleles				Risk alleles				Risk alleles			
Progressed?		0	1	2	NA	0	1	2	NA	0	1	2	NA
<b>ARMS2</b> <b>rs10490924</b>	yes	70	74	22	-	34	28	9	-	36	46	13	-
	no	180	146	55	-	180	146	55	-	180	146	54	-
	<b>total</b>	<b>250</b>	<b>220</b>	<b>77</b>	-	<b>214</b>	<b>174</b>	<b>64</b>	-	<b>216</b>	<b>192</b>	<b>67</b>	-
		(169)	(150)	(53)		(145)	(121)	(45)		(151)	(133)	(46)	
<b>CFH</b> <b>rs10737680</b>	yes	9	42	116	-	3	19	50	-	6	23	66	-
	no	22	136	222	-	22	136	222	-	22	136	222	-
	<b>total</b>	<b>31</b>	<b>178</b>	<b>338</b>	-	<b>25</b>	<b>155</b>	<b>272</b>	-	<b>28</b>	<b>159</b>	<b>288</b>	-
		(20)	(123)	(229)		(18)	(107)	(186)		(19)	(112)	(199)	
<b>CFH</b> <b>rs1061170</b>	yes	30	77	58	2	14	31	25	2	16	46	33	0
	no	78	179	121	2	78	179	121	2	78	179	121	2
	<b>total</b>	<b>108</b>	<b>256</b>	<b>179</b>	<b>4</b>	<b>92</b>	<b>210</b>	<b>146</b>	<b>4</b>	<b>94</b>	<b>225</b>	<b>154</b>	<b>2</b>
		(75)	(173)	(121)	(3)	(68)	(142)	(99)	(3)	(68)	(154)	(106)	(2)
<b>C2</b> <b>rs429608</b>	yes	2	20	145	-	0	12	60	-	2	8	85	-
	no	4	56	320	-	4	56	320	-	4	56	320	-
	<b>total</b>	<b>6</b>	<b>76</b>	<b>465</b>	-	<b>4</b>	<b>68</b>	<b>380</b>	-	<b>6</b>	<b>64</b>	<b>405</b>	-
		(4)	(52)	(316)		(3)	(45)	(263)		(4)	(46)	(280)	
<b>C2</b> <b>rs9332739</b>	yes	1	3	161	2	-	2	68	2	1	1	93	0
	no	0	18	360	2	-	18	360	2	0	18	360	2
	<b>total</b>	<b>1</b>	<b>21</b>	<b>521</b>	<b>4</b>	<b>-</b>	<b>20 (13)</b>	<b>428</b>	<b>4</b>	<b>1</b>	<b>19</b>	<b>453</b>	<b>2</b>
		(1)	(13)	(355)	(3)			(295)	(3)	(1)	(12)	(315)	(2)
<b>CFB</b> <b>rs641153</b>	yes	0	16	149	2	0	5	65	2	0	11	84	0
	no	1	27	350	2	1	27	350	2	1	27	350	2
	<b>total</b>	<b>1</b>	<b>43</b>	<b>499</b>	<b>4</b>	<b>1</b>	<b>32</b>	<b>415</b>	<b>4</b>	<b>1</b>	<b>38</b>	<b>434</b>	<b>2</b>
		(1)	(31)	(337)	(3)	(1)	(22)	(285)	(3)	(1)	(28)	(299)	(2)
<b>C3</b> <b>rs2230199</b>	yes	84	70	13	-	32	34	6	-	52	36	7	-
	no	218	130	32	-	218	130	32	-	218	130	32	-
	<b>total</b>	<b>302</b>	<b>200</b>	<b>45</b>	-	<b>250</b>	<b>164</b>	<b>38</b>	-	<b>270</b>	<b>166</b>	<b>39</b>	-
		(207)	(135)	(30)		(172)	(114)	(25)		(189)	(115)	(26)	

**Table S2.** Multivariate regression coefficients and hazard ratios (HR) from Cox proportional hazards models testing whether progression rate from intermediate to advanced (grades 4 or 5) varied with genotype at 7 variants associated with risk of advanced AMD after controlling for variation due to age and sex. Contrasts from the intercept (females with 0 risk alleles) are reported. Significant variables are shown in bold. Models were relevelled to give contrasts between 2 and 1 risk alleles (shown in italic).


variable	coef	se (coef)	HR (95% CI)	p-value
<b>Age</b>	<b>0.05</b>	<b>0.01</b>	<b>1.05 (1.03-1.08)</b>	<b>&lt;0.001</b>
Sex (M)	0.03	0.17	1.03 (0.71-1.50)	0.878
ARMS2: rs10490924 (GT)	0.22	0.18	1.24 (0.85-1.81)	0.254
ARMS2: rs10490924 (TT)	0.06	0.27	1.06 (0.55-2.05)	0.870
ARMS2: rs10490924 ( <i>TT</i> vs. <i>GT</i> )	-0.16	0.27	0.85 (0.43-1.66)	0.632
CFH: rs10737680 (CA)	-0.81	0.43	0.45 (0.16-1.26)	0.128
CFH: rs10737680 (AA)	-0.27	0.42	0.77 (0.27-2.18)	0.618
<b>CFH: rs10737680 (AA vs. CA)</b>	<b>0.54</b>	<b>0.22</b>	<b>1.72 (1.06-2.79)</b>	<b>0.029</b>
CFH: rs1061170 (TC)	0.26	0.25	1.30 (0.75-2.26)	0.347
CFH: rs1061170 (CC)	-0.10	0.28	1.10 (0.60-2.02)	0.755
<i>CFH: rs1061170 (CC vs. TC)</i>	-0.17	0.20	0.84 (0.55-1.29)	0.436
C2: rs429608 (GG)	0.39	0.46	1.48 (0.70-3.11)	0.307
C2: rs9332739 (GG)	0.15	0.66	1.17 (0.42-3.26)	0.768
CFB: rs641153 (GG)	-0.75	0.49	0.47 (0.20-1.10)	0.082
C3: rs2230199 (GC)	0.02	0.17	1.02 (0.70-1.49)	0.916
C3: rs2230199 (CC)	-0.30	0.31	0.74 (0.36-1.52)	0.401
<i>C3: rs2230199 (CC vs. GC)</i>	-0.32	0.32	0.73 (0.35-1.53)	0.400

### Supplementary Figure 1 Survival curves for progression to advanced AMD (GA or CNV)

Survival curves showing the predicted progression rate from intermediate (grade 3) to advanced (grades 4 or 5) AMD with respect to the number of risk alleles at a) *ARMS2*:rs10490924, b) *CFH*:rs1061170, c) *C2*:rs429608, d) *C2*:rs9332739, e) *CFB*:rs641153, and f) *C3*:rs2230199 for females of 67 years of age.



e) C2 rs641153



f) C3 rs2230199

